Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiothixene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 5/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HTR6 | P50406 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiothixene SCHEMBL782605 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL34305 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL29391417 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL3715363 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL29373233 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL561321 | 0.99 | MEN1 (1.00) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL40977 | 0.98 | MEN1 (0.98) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL30903897 | 0.98 | MEN1 (0.98) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL721093 | 0.97 | CYP3A4 (0.94) | CYP3A4LMNADRD3CYP2D6HTR1A | |
| Thiothixene SCHEMBL8022212 | 0.95 | CYP3A4 (0.91) | CYP3A4LMNADRD3CYP2D6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4107430-A | Conversion of trans- to cis-N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-thioxanthene-2-sulfonamide and recovery of the cis-isomer | PFIZER INC. (US) | 1978-08-15 | — | — | US | claimed |
| US-20220370620-A1 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-24 | — | — | US | disclosed |
| US-20210393645-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2021-12-23 | — | — | US | disclosed |
| US-20200368358-A1 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-11-26 | — | — | US | disclosed |
| US-10736965-B2 | Risperidone biodegradable implant | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190262353-A1 | TREATMENT FOR PROGRESSIVE MULTIPLE SCLEROSIS | UTI LIMITED PARTNERSHIP (CA) | 2019-08-29 | — | — | US | disclosed |
| US-20190105396-A1 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2019-04-11 | — | — | US | disclosed |
| US-10111960-B2 | 9-OH-risperidone controlled release composition | THE TRUSTREES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180125984-A1 | DRUG-CONTAINING IMPLANTS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2018-05-10 | — | — | US | disclosed |
| US-9925268-B2 | Drug-containing implants and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-03-27 | — | — | US | disclosed |
| WO-2002022114-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF SEXUAL DYSFUNCTION | SEPRACOR INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-20020010198-A1 | Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds | SEPRACOR, INC. | 2002-01-24 | — | — | US | disclosed |
| US-6339106-B1 | ADMINISTERING A RACEMIC OR OPTICALLY PURE SIBUTRANINE METABOLITE SUCH AS DESMETHYLSIBUTRAMINE, DIDESMETHYLSIBUTRAMINE OR ITS SALT OR SOLVATE OR CLATHRATE FOR THERAPY OF SEXUAL DYSFUNCTION | SEPRACOR, INC. | 2002-01-15 | — | — | US | disclosed |
| US-6331571-B1 | ADMINISTERING THERAPEUTICALLY OR PROPHYLACTICALLY EFFECTIVE AMOUNT OF RACEMIC OR OPTICALLY PURE SIBUTRAMINE METABOLITE, OR PHARMACEUTICALLY ACCEPTABLE SALT, SOLVATE, OR CLATHRATE THEREOF | SEPRACOR, INC. | 2001-12-18 | — | — | US | disclosed |
| WO-2001051453-A1 | RACEMIC AND OPTICALLY PURE METABOLITES OF SIBUTRAMINE, THEIR PREPARATION, COMPOSITIONS COMPRISING THEM AND THEIR USE AS DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1107746-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | Sepracor Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010551-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| US-4107430-A | Conversion of trans- to cis-N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-thioxanthene-2-sulfonamide and recovery of the cis-isomer | PFIZER INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4107430-A | Conversion of trans- to cis-N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-thioxanthene-2-sulfonamide and recovery of the cis-isomer | PFIZER INC. (US) | 1978-08-15 | — | — | US | disclosed |
| US-4107430-A | Conversion of trans- to cis-N,N-dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]-thioxanthene-2-sulfonamide and recovery of the cis-isomer | PFIZER INC. (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010198-A1 | Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds | OPRL1, OPRM1, OPRK1 | DRD2 41/4885HTR2A 17/4885CYP3A4 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.